Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

ERK Inhibition Does Not Enhance BEACON Regimen Efficacy in Untreated BRAF V600E–Mutated CRC

June 30th 2024

Aparna Parikh, MD, discusses key findings from the HERKULES-3 study and what the future of the BRAF-mutated mCRC treatment paradigm may look like.

Dr Chao on the Association Between Broad-Spectrum Antibiotic Use and the Risk of Early-Onset CRC

June 28th 2024

Chun Chao, MS, PhD, discusses the impact of broad-spectrum antibiotic use on the risk of developing early-onset colorectal adenocarcinoma.

TAS-102 Followed By Regorafenib Identified As Optimal Treatment Sequence in Pretreated mCRC

June 28th 2024

TAS-102 followed by regorafenib is an optimal sequence vs regorafenib followed by TAS-102 in select patients with metastatic colorectal cancer.

Dr Kyriakopoulos on Evaluating Biomarkers and Disease Progression with CTC Analysis in CHAARTED2 trial

June 28th 2024

Christos Kyriakopoulos, MD discusses two correlative studies conducted within the CHAARTED2 trial.

Do Tumor-Naive MRD Assays Have a Role in Resected CRC? Cremolini Weighs in

June 28th 2024

Chiara Cremolini, MD, discusses the role of ctDNA in assessing minimal residual disease in patients with CRC.

Dr Fakih on OS Data for Sotorasib Plus Panitumumab in KRAS G12C+ mCRC

June 27th 2024

Marwan G. Fakih, MD, discusses data for sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

Adding Celecoxib to Adjuvant Chemotherapy Offers DFS, OS Benefit in PIK3CA-Mutated Stage III Colon Cancer

June 27th 2024

Celecoxib plus adjuvant chemotherapy led to extended DFS and OS vs placebo plus adjuvant chemotherapy in PIK3CA-mutated stage III colon cancer.

Cetuximab Biosimilar Receives NMPA Approval For RAS/BRAF Wild-Type CRC

June 26th 2024

First-line cetuximab beta injection has received NMPA marketing approval in RAS/BRAF wild-type metastatic colorectal cancer.

Fruquintinib Wins European Approval for Pretreated mCRC

June 24th 2024

The European Commission has approved fruquintinib for select patients with pretreated metastatic colorectal cancer.

FDA Approves Adagrasib Plus Cetuximab for KRAS G12C–Mutant CRC

June 21st 2024

The FDA has approved adagrasib plus cetuximab for patients with KRAS G12C–mutant locally advanced or metastatic colorectal cancer.

Dr Marshall on Updates in CRC Following the 2024 ASCO Annual Meeting

June 17th 2024

John L. Marshall, MD, discuss updates in colorectal cancer management at the 2024 ASCO Annual Meeting.

Dr Adam on the Efficacy of Liver Transplantation With Chemo in Unresectable CRC Liver Metastases

June 7th 2024

Rene Adam, MD, PhD, discusses the use of chemotherapy and liver transplant in patients with definitively unresectable colorectal liver metastases.

Dostarlimab 2 for 2: Snagging 100% Clinical CR in dMMR Locally Advanced Rectal Cancer

June 3rd 2024

In a phase 2 trial, all 42 patients with locally advanced mismatch repair–deficient rectal cancer achieved clinical complete response with dostarlimab.

Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC

June 3rd 2024

Lenz discusses the link between HER2 expression and responses with mCRC treatment regimens and how HER2 expression can guide treatment decision-making.

Bevacizumab Biosimilar Avzivi Receives Positive CHMP Opinion

June 3rd 2024

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for Avzivi, a monoclonal antibody referencing bevacizumab.

Liver Transplantation Plus Chemotherapy Improves 5-Year OS Rate in Patients With CRC Liver Metastases

June 2nd 2024

Integrating liver transplantation into treatment with chemotherapy improved survival at 5 years vs chemotherapy alone in patients with definitively unresectable CRC liver metastases.

OncLive’s May Roundup of Key FDA Approvals in Oncology

May 31st 2024

Here is your guide to important regulatory approvals made by the FDA in May 2024.

Revisit Every OncLive On Air Episode From May 2024

May 30th 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

FDA Advisory Committee Recommends Approval of Shield Blood Test for CRC Detection in Average-Risk Adults

May 24th 2024

The FDA’s Medical Devices Advisory Committee recommends the approval of the Shield blood test for CRC screening in adults at average risk for CRC.

Dr Bou Farhat on a Retrospective Study of NGS vs IHC Sensitivity for dMMR CRC and Endometrial Cancer

May 22nd 2024

Elias Bou Farhat, MD, discusses an investigation of NGS sensitivity vs standard IHC alone in the assessment of dMMR colorectal cancer or endometrial cancer.